|Bid||2.5200 x 3000|
|Ask||2.5300 x 2200|
|Day's range||2.4000 - 2.5200|
|52-week range||2.0200 - 6.3100|
|Beta (5Y monthly)||1.36|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.69|
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2023 (FY2023) third quarter after the market closes on Wednesday, February 8, 2023. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss th
The current economic environment, however, has pushed several intriguing, innovation-oriented companies into penny stock territory. Although these names are still exceedingly high-risk, I think aggressive investors may want to consider buying shares of Precigen (NASDAQ: PGEN), Rigel Pharmaceuticals (NASDAQ: RIGL), and 23andMe Holding Company (NASDAQ: ME) right now. Read on to find out why these three low-priced equities might be a tremendous wealth escalator for patient shareholders.
If you want to know who really controls 23andMe Holding Co. ( NASDAQ:ME ), then you'll have to look at the makeup of...